Your pipeline asset took years to develop. The partnership that was supposed to bring it to market has broken down. Now a tribunal needs to put a number on what it was worth - before the data was in, before regulatory approval, before a single patient was treated.
This is the reality of life sciences arbitration. At the 2026 Paris Arbitration Week, Bird & Bird's Flore Poloni and Mario Subramaniam joined quantum experts from FTI Consulting and an investor from Sofinnova Partners to explore how tribunals approach this challenge - and how the agreements you sign today will shape your position if a collaboration breaks down tomorrow.
From milestone definitions and diligence obligations to the assumptions that drive damages models, the detail of your contracts matters more than you might think.

/Passle/65b10a249576f7f0a5a2f163/MediaLibrary/Images/2026-11-09-15-01-48-320-6af1e05c782e02379982fa43.jpg)
/Passle/MediaLibrary/Images/2026-08-19-11-49-43-432-6a859857d078d714566ff176.jpg)
/Passle/65b10a249576f7f0a5a2f163/MediaLibrary/Images/2026-11-06-11-08-51-186-6aedb5430703695507e8f984.jpg)
/Passle/MediaLibrary/Images/2026-03-17-12-44-11-469-69b94c9bf137f34ddd786b3b.jpg)